Avidity Biosciences, Inc. has announced the record date for the pro rata distribution of all issued and outstanding shares of common stock of Atrium Therapeutics, Inc. to holders of Avidity common stock. The record date is February 12, 2026, and each holder will receive one share of SpinCo common stock for every ten shares of Avidity common stock held on the record date.
Avidity Biosciences is committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to improve people's lives. The company has demonstrated successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: Myotonic Dystrophy Type 1 (DM1), Duchenne Muscular Dystrophy (DMD), and Facioscapulohumeral Muscular Dystrophy (FSHD). Additionally, Avidity is advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies and broadening the reach of AOCs with advancing and expanding pipeline programs in cardiology and immunology through key partnerships.
The completion of the merger and the spin-off remains subject to certain closing conditions, including the receipt of Avidity stockholder approval. Avidity is headquartered in San Diego, California. Today the company's shares have moved -0.12% to a price of $72.51. For the full picture, make sure to review Avidity Biosciences's 8-K report.
